Davis Polk advised the joint book-running managers in connection with a $176 million SEC-registered offering of 5,500,000 shares of common stock of Aimmune Therapeutics, Inc.

Aimmune Therapeutics is a biopharmaceutical company developing treatments for potentially life-threatening food allergies.

The Davis Polk corporate team included partner Stephen Salmon and associates Marcus K. Hintze, Josephine Chen and Dylan Service. The tax team included partner Rachel D. Kleinberg. The intellectual property and technology team included counsel Michelle Ontiveros Gross and associate Jason J. Bang. Jennifer L. Rose was the legal assistant on the transaction. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post